Tempest’s third makeover
The cash-strapped biotech adds Car-T projects but tries to avoid a lawsuit.
Zymeworks moves to repeat the Ziihera trick
The company adds royalty aggregation to its R&D business.
For $3bn J&J holds on to Halda
The private biotech adds another asset to J&J’s prostate cancer pipeline.
Mersana gets its rescue bid
But the Day One deal is still 29% below where the shares stood at the start of this year.
Lyell shuffles the pipeline again
After more discontinuations, a new deal brings in fresh blood.
Venture capitalists buy into TROP2
Blackstone follows Abingworth, but why?
